Biofrontera AG (BFRA) News

Biofrontera AG (BFRA): $6.09

-0.20 (-3.18%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BFRA News Items

BFRA News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BFRA News Highlights

  • 500 - Internal server error
  • Over the past 17 days, the trend for BFRA's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about BFRA are AG.

Latest BFRA News From Around the Web

Below are the latest news stories about Biofrontera AG that investors may wish to consider to help them evaluate BFRA as an investment opportunity.

Biofrontera enters into license and supply agreement with Medac for the marketing of Ameluz® in Poland

Leverkusen, Germany, July 23, 2021 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Medac Gesellschaft für klinische Spezialpräparate mbH. (Medac), signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Poland. The agreement has a term of 5 years commencing with the start of sales in Poland. Under the terms of the agreement, Medac will make an immediate one-t

Yahoo | July 23, 2021

Biofrontera Inc. seeks IPO in the USA

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG currently holds 100 % of the shares of the US-based Biofrontera Inc. Biofrontera AG had already announced that opportunities for capital raises were being evaluated including a potential initial public offering ("IPO") of Biofrontera Inc. in the United States. The main objectives of an IPO of Biofrontera Inc. would be to

Wallstreet:Online | July 6, 2021

Biofrontera reports preliminary revenue for the month of June 2021

Leverkusen, Germany, July 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of June 2021.

Intrado Digital Media | July 6, 2021

Biofrontera Stock Moves Higher On Outlining Clinical Update

Biofrontera AG (NASDAQ: BFRA) has provided an update on two submissions to the FDA, enabling the simultaneous use of up to three tubes of Ameluz per photodynamic therapy (PDT) on the one hand while seeking approval for a larger red-light lamp BF-RhodoLED XL, on the other. About the approval process of BF-RhodoLED, the FDA has confirmed that the data are sufficient for the submission and that the evaluation process will be initiated. Regarding the other submission, the agency did not express any

Yahoo | June 22, 2021

Biofrontera provides update on clinical developments

Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an update on its clinical developments. In February and March 2021, the Company announced two submissions to the U.S. Food and Drug Administration (FDA), enabling the simultaneous use of up to three tubes of Ameluz® per photodynamic therapy (PDT) on the one hand, while seeking approval for a larger red-ligh

Yahoo | June 22, 2021

Biofrontera reports preliminary revenue for the month of May 2021

Leverkusen, Germany, June 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the Company), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of May 2021.

GlobeNewswire | June 7, 2021

Biofrontera reports Q1 2021 financial results

Leverkusen, Germany, May 11, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported its financial results for the first quarter ended March 31, 2021. Q1 2021 key financial figures and business performance In EUR thousands3M 20213M 2020ChangeRevenue5,479 6,473 (15)%Gross profit on sales4,578 5,674 (19)%Research and development costs(1,317)(1,311)0%General and administrative costs(2,538)(2,232)14%Sales and marketing costs(4,813)(8,698)(45)%Profit (loss) on operations(4,089)(6,567)(38)%EBITDA(3,158)(2,645)19%EBIT(3,971)(5,555)(29)%Earnings (loss) before tax(4,876)(5,498)(11)%Earnings (loss) after tax(4,877)(5,499)(11)% Biofrontera's business performance was encouragingly positive afte...

Yahoo | May 11, 2021

Biofrontera reports preliminary revenue for the month of April 2021

Leverkusen, Germany, May 06, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the month of April 2021. The Company’s preliminary, unaudited revenue from product sales in April 2021 amounted to approximately EUR 2,491 thousand, compared to EUR 492 thousand in April 2020, an increase of 406%. Total revenue for the month of April 2020 was EUR 6,602 thousand, whereby April 2020 included a one-time down payment of EUR 6,000 thousand from Maruho Co., Ltd as part of a license and supply agreement. Preliminary revenues from product sales in the US were around EUR 1,821 thousand compared to EUR 333 thousand in April 2020, an increase of 447%. In Germ...

Yahoo | May 6, 2021

Biofrontera submits study report of pharmacokinetics study to FDA

Leverkusen, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces the submission of an application to the U.S. Food and Drug Administration (FDA) to amend the product information to allow the simultaneous use of three tubes of Ameluz®. The application is supported by a phase I pharmacokinetics (PK) study for the treatment of actinic keratoses with three tubes of Ameluz®. In October 2020 (refer to our press release dated October 8, 2020), the Company was able to complete the clinical phase of the PK study, which tested the safety of photodynamic therapy (PDT) with the simultaneous use of three tubes of Ameluz® on larger or multiple areas. Subsequently, the study data w...

Yahoo | February 24, 2021

Biofrontera Raises $8.9M Via Equity Offering

Biofrontera AG (NASDAQ: BFRA) priced an underwritten public offering of around 1.3 million ADS at $6.68 per ADS, raising gross proceeds of approximately $8.9 million. The offer price represents a discount of 5% from the last close price of $7.04 on Tuesday. Each ADS represents two of BFRA's ordinary shares. The offering will close by February 26. This offer is part of concurrent preemptive rights offered to the company's ordinary shares holders of around 8.9 million ordinary shares at €2.75 per share. Proceeds will be used for regulatory approval for expanded use of its lead product Ameluz, in the U.S. to basal cell carcinoma, acne, and actinic keratoses, complete the development of a larger BF-RhodoLED lamp, and for general corporate purposes. The Benchmark Company is acting as the man...

Yahoo | February 24, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6044 seconds.